Abel, G. &
Czop, J.K.; - "Stimulation of human monocyte beta-glucan receptors
by glucan particles induces production of TNF-alpha and IL-1 beta,
"Int. J. Immunopharmacolol, 14: 1363-1373. 1992.*
Abel, G. &
Czop, J.K., - "Activation of Human Monocyte GM-CSF and TNF-alpha.
Production by Particulate Yeast Glucan," International Congress
for Infectious Diseases, Montreal, Canada (abstract). 1990.
* Dept of Medicine, Harvard Medical School, Boston, MA. Quote:
"Beta-glucans are pharmacological agents that rapidly enhance
the host resistance to a variety of biologic insults through mechanisms
involving macrophage activation."
Adachi Y.,
Ohno N., Yacomae T.; - "Preparation and antigen specificity of
an anti- (1-->3)-beta-D-glucan antibody," Biol Pharm bull
17: 1508-1512; 1994. *
Adachi Y.,
Ohno N., Yacomae T.; - "Inhibitory effect of beta-glucans on Zymosan-mediated
hydrogen peroxide production by murine peritoneal macrophages
in vitro," Biol Pharm Bull, 16: 462-467; 1993.
Adachi Y.,
Ohno N., Ohsawa M., Oikawa S.,Yacomae T.; - "Macrophage
activation in vitro by chemically cross-linked (1--3)-beta-D-glucans,"
Chem Pharm Bull (Tokyo), 38:988-992 1990. Laboratory of
Immunopharmacology of Microbial Products, Tokyo College of Pharmacy,
Japan. *
Ainsworth
A.J., - "A beta-glucan inhibitable Zymosan receptor on channel
catfish neutrophils," Vet Immunol Immunopathol, 41:
141-152. 1994. *
Almdahl SM,
Bogwald J, Hoffman J, Seljelid R; - "Treatment of experimental
peritonitis in rats by transfer of peritoneal mononuclear
cells from rats injected with semisoluble aminated glucan."
Acta Chir Scand 153(9): 535-539, Sep 1987. Dept of Surgery,
University Hospital, Tromso, Norway. *
Almdahl SM,
Bogwald J, Hoffman J, Seljelid R; - "The effect of splenectomy
on Escherichia coli sepsis and its treatment with semisoluble
aminated glucan," Scand J Gastroenterol 22(3): 261-267; Apr
1987. *
Almdahl SM,
Bogwald J, Hoffman J, Seljelid R Giercksky KE; - "Protection by
aminated glucan in experimental endogenous peritonitis,"
Eur Surg Res 19(2): 78-85, 1987. *
Almdahl SM,
Seljelid R; - "Semisoluble animated glucan: long-term efficacy
against an intraperitoneal E. coli challenge and its effect
on formation of abdominal adhesions," Res Exp Med (Berlin)
187(5): 369-377, 198 . *
Alpha-Beta
Corporation-Annual Report 1994; PGG-glucan, 1994. *
Andaluz E.,
Guillen A., Larriba G.; - "Preliminary evidence for a glucan acceptor
in the yeast Candida albicans," Biochem J.; 240: 495-502.
1986.
Anti-free
Radical Activity of Beta (1-3) glucan Molecule. Seporga Laboratories,
Sophia Antipolis, France. Research Report. 1990.
AOKI, - Immunomodulating
Agents: Properties and Mechanisms, Chirigos, eds, Marcel Dekker,
1984; 20:63-77. 1984.
Aono R., Hammura
M. et al; - "Isolation of extracellular 28- and 42-kilodalton
beta-1-3-glucanases and comparison of three beta-1, 3-glucanases
produced by Bacillus circulans IAM1165," Appl. Environ.
Microbiol 61: 122-129.1995
Artursson
P et al; - "Macrophage stimulation with some structurally
related polysaccharides," Scand J Immunol 25(3): 245-254, Mar
1987. *
Babineau,
et al., - "A Phase II Multicenter, Double-Blind Randomized, Placebo-Controlled
Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High
Risk Surgical Patients", Arch. Surg.; 129:1204-1210. 1994.
Dept of Surgery, Deaconess Hospital, Harvard Medical School, Boston
MA. *
Babineau,
et al., - "Randomized Phase I/II Trial of a Macrophage-Specific
Immunomodulator (PGG-Glucan) in High Risk Surgical Patients",
Annals of Surgery; 220: (5): 601-609. 1994. Dept of Surgery,
Deaconess Hospital, Harvard Medical School, Boston MA. * Quote:
"PGG-glucan is safe and appears to be effective in further
reduction of the morbidity and cost of major surgery."*
Bacon J.,
et al., - "The Glucan Components of the Cell Wall of Baker's Yeast
(Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure,"
Chemical Abstracts, 71:109168c. 1991.
Bacon J.,
et al., - "The Glucan Components of the Cell Wall of Baker's Yeast
(Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure,"
Biochem J.; 114:557-567. 1969.
Baird et al.,
- "Investigation of the Polysaccharides Produced by Extracellular
Glycosyltransferases from Streptococcus Mutans," Chemical Abstracts;
vol. 77, No. 11, p. 242. Abs. No. 72399z. 1972.
Ballou CE;
- "The yeast cell wall and cell surface;" The Molecular Biology
of the Yeast Saccharomyces. Cold Spring Harbor Laboratories. New
York. p 335; 1982.
Barlin, et
al., - Heterogeneity of Molecular Phagocytes, Forster & Landy,
eds., Academic Press, New York, pp. 243-252. 1981.
Benach J.L.,
et al., - "Glucan as an adjuvant for a murine Babesia microti
immunization trial," Infection and Immunity, 35(3): 947-951.
1982. Quote: "These observations demonstrate that glucan
is an effective adjuvant in enhancing immunity to murine babesiosis."*
Beta (1-3)
glucan 1.3 Glucan Activity in Mice: Intraperitoneal and Oral
Applications. Baylor College of Medicine. Research Summary.
1989.
Beta (1-3)
glucan: "I1-1 Cytokine Release after Oral Application in
Mice". Baylor College of Medicine. Research Report. 1994.
Bogwald J,
Johnson E, Hoffman J, Seljelid R, - "Lysosomal Glycosidase
in Mouse Peritoneal Macrophages Stimulated in Vitro with Soluble
and Insoluble Glucans". J. Leukocyte Biol.; 35: 357-371. 1984.
*
Bogwald J,
Johnson E, Seljelid R; - "The Cytotoxic Effect of Mouse Macrophages
Stimulated in vitro by a beta. 1,3-D-Glucan from Yeast Cell Walls".
Scand. J. Immuol. 15: 297-304. 1982. Institute of Med Bio,
U of Tromso, Norway. Quote: " Macrophages stimulated by an
insoluble beta 1-3-D-glucan from yeast cell walls were able to
destroy tumor cells as measured by the release of radioactive
label from prelabelled 14C-thymidine cells. Target cells were
B-16 melanoma, P-815 mastocytoma, and the L-929 cell line. A significant
target cell killing by macrophages stimulated by glucan was observed
after 72-96 h."
Bone, R.C.,
- /Gram-negative sepsis. Background, clinical features
and intervention. Chest; 100:802-808. 1991.
Bomford and
Moreno, - "Mechanisms of the Anti-Tumor Effect of Glucans
and Fructosans: A Comparison with C. Parvum". Br. J. Cancer;
36:41-48. 1977.
Boone C, Sdicu
A, Laroche M, Bussey H; - "Isolation from Candida albicans
of a functional homolog of the Saccharomyces cerevisiae KRE1 Gene,
which is involved in cell wall beta-glucan synthesis," J Bacteriol
173(21); 6859-6864, Nov 1991. *
Boone C.,
Sommer SS, Hensel A., Bussey H., - "Yeast KRE genes provide evidence
for a pathway of cell wall beta-glucan assembly," J Cell Biol;
110: 1833-1843. 1990.
Borriss, et
al., - "Molecular cloning of a gene coding for thermostable beta-glucanase
from Bacillus macerns," J. Basic Microbiol; 28:3-10. 1988.
Borriss, et
al., - "Expressions in Escherichia coli of a cloned beta-glucanase
gene from Bacillus Amyloliquefaciens," Appl. Microbiol. Biotechnol;
22:63-71. 1985.
Borriss, -
Purification and characterization of an extracelluar beta-glucanase
from Bacillus IMET B376 (1)), Z. Alg. Mikrobiologie; 21:7-17.
1981.
Borriss, et
al., - "Beta-1, 3-1,4-glucanase in sporeforming microorganisms.
V. The efficiency of beta-glucanase in reducing the viscosity
of wort", Zbl. Bakt II Abt. 136:324-329. 1981.
Bousquet M.,
Escoula L. et al; "Immunopharmacologic study in mice of 2 beta-1,
3, beta-1, 6 polysaccharides (Scleroglucan and PSAT) on the activation
of macrophages and T lymphocytes," Ann Rech Vet 20:
165-173. 1989. Station of Pharmacologie-Toxicologie, INRA,
Toulouse, France. * Quote: "...PSAT and scleroglucan favorably
affect the non-specific host defense and cellular immune response
in mice."
Bousquet M.,
Escoula L., Pippy B, Besssieres MH, Chavant L, Seguela JP, "Enhancement
of Resistance of mice Toxoplasma gondi by 2 polysaccharides beta
(1-3) glucan 1-3, beta (1-3) glucan 1-6 (PSAT and Scleroglucan)"
Ann Parasitol Hum Comp., ^63 (6): 398-409. 1988. *
Bowers G.,
J. Patchen MLl, et al, "Glucan enhances survival in an intraabdominal
infection model," J Surg Res 47(2): 183-188; Aug 1989. *
Broach JR,
Pringle JR and Jones EW; "The Molecular and Cellular Biology of
the Yeast Saccharomyces cerevisiae;" Genome Dynamics, Protein
Synthesis, and Energetics; Cold Springs Harbor Laboratory Press,
Cold Spring Harbor, New York. 1991.
Browder W.,
Williams D., Pretus H., et al; Beneficial Effect of Enhanced Macrophage
Function in the Trauma Patients. Ann. Surg.; Vol 211: 605-613.
1990. Dept of Surg and Physiol, Tulane U Sch of Med, LA and Istituto
Di Chirurgia D'Urgenza, U of Torino, Torino, Italy. * Quote: "Previous
studies have demonstrated that glucan, a beta-1, 3-linked glucopyranose
polymer, isolated from the inner cell wall of Saccharomyces cerevisiae,
is a potent macrophage stimulant and is beneficial in the therapy
of experimental bacterial, viral, and fungal diseases. Use of
glucan in a murine model of hind-limb crush injury decreased macrophage
PGE2 release while stimulating bone marrow proliferation."
Browder Iw,
Sherwood E., Williams D., Jones E., Mcnamee R., Diluzio N., "Protective
effect of glucan-enhanced macrophage function in experimental
pancreatitis", Am J Surg.; 1153 (1): 25-33. 1987.
Browder W.,
Williams D., Sherwood E., McNamee R., Jones E., Diluzio N., "Synergistic
effect of nonspecific immunostimulation and antibiotics in experimental
peritonitis", Surgery 102 (2): 206-214. 1987*
Browder W.,
et al., "Modification of Post-Operative C. albicans Sepsis by
Glucan Immunostimulation," Int. J. Immunopharmac.; 6:19-26.
1984. Dept of Surg and Physiol, Tulane U Sch of Med, LA Quote:
"These observations suggest that Biologic Response Modifiers such
as glucan may be effectively employed in patients who are at risk
for post-operative infections."*
Browder W.,
et al., "Protective Effect of Nonspecific Immunostimulation in
Post Splenectomy Sepsis". J. Surg. Res.; 35: 474-479. 1983.
Dept of Surg and Physiol, Tulane U Sch of Med, LA * Quote:
"This study reports the use of glucan, a beta-1, 3-polyclucose,
as a nonspecific immunostimulant for postsplenectomy pneumococcal
sepsis. ...Nonspecific immunostimulation appears to have significant
potential as a treatment strategy against postplenectomy infection."
Browder, W.,
Survey of Immunological Research, 1983; 2:229-301. 1983.
Browder W.,
et al., Immunomodulation by Microbial Products and Related Synthetic
Compounds, Yamamura et al., eds. Excerpta Medica, Amsterdam;
pp. 354-357. 1982.
Brown Jl,
et al; "A mutational analysis of killer toxin resistance in Saccharomyces
cerevisiae identifies new genes involved in cell wall (1-->6)-beta-glucan
synthesis," Genetics 133(4) 837-849, Apr 1993. *
Buddle BM,
et al, "Protective effect of glucan against experimentally
induced staphylococcal mastitis in ewes." Vet Microbiol
16(1): 67-76, Jan 1988.
Bulone V.,
Fevre m.; "A 34-kilodalton polypeptide is associated with 1,3-beta-glucan
synthase activity from the fungus Saprolegnia monoica," FEMS
Microbiol Lett: 140: 145-150, 1996.
Burgaleta
C., Goide D. W.; Increased granulopoiesis and macrophage production
in glucan-treated mice; Chirigos MA, ed. Immune Modulation
and Control of Neoplosia by Adjuvant Therapy. New York: Raven
Press, 195-219, 1978.
Burgaleta
C., Territo M.C., Quan C.G., Goide D.W.; Glucan activated macrophages:
functional characteristics and surface morphology; J Reticuloendothel
Soc 23: 195-204. 1978.
Burgaleta,
C. and Golde, D.W.; "Effect of Glucan on Granulopoiesis
and Macrophage Genesis in Mice". Cancer Research; 37:1739-1742;
Jun 1977. *
Cain J.A.,
Newman S.L., Ross G.D., "Role of complement receptor type three
and serum opsonins in the neutrophil response to yeast," Complement
4: 75-86.1987.
Campbell I
And Duffus jh; eds., "Yeast." 1988.
Carrow, D.J.;
"Beta-1, 3-glucan as a Primary Immune Activator," Townsend
Letter; June 1996.
Cerenius L.,
Liang Z., Duvie B., et al, "Structure and biological activity
of a 1,3 beta-D-glucan-binding protein in crustacean blood," J.
Biol Chem 269: 29462-29467. 1994.
Chen Y-h Riby
Y., Srivastava P., Bartholomew J., Denison M, Bjeldanes L.; Regulation
of CYP1A1 by Indolo{3,2-b} Carbazole in Murine Hepatoma Cells.
J Biol Chem.; 270(38): 22548-55. 1995.
Chihara G.,
et al., "Lentinan as a Host Defense Potentiator (HPD)," Int.
J. Immunotherapy; V (4): 145-154. 1989.
Chihara G.,
Rivista di Immunolog, ed. Immunofarm.; 5: (2): 85-97. 1983.
Chirigos M.A.,
et al, Cancer Research; 38:1085-1091. 1978.
Cisreros RL,
Gibson FC 3, Tzianabos AO; "Passive transfer of poly- (1-6)-beta-Glucotrisyl-
(1-3)-beta glucopyranose glucan protection against lethal infection
in an animal model of intra-abdominal sepsis," Infect Immun
64(6): 2201-2205, Jun 1996. Channing Laboratory, Brigham and Women's
Hospital, Boston, MA. *
Clark A.E.,
Stone B.A.; "Beta-glucan hydrolases from Aspergillus niger. Isolation
of a beta- (1-4)-glucan hydrolase and some properties of the beta-
(1-3)-glucan-hydrolase components," Bichem J 96: 793-801. 1965.
Cook J. A.,
et al, Infection and Immunity; 40(3): 1038-1043. 1983.
Cook J. A.,
et al, "Immunomodulation of Protozoan Diseases". Immunolg.
Res.; 2: 243-245. 1983.
Cook J. A.,
et al, "Protective Effect of Glucan against Visceral Leishmaniasis
in Hamsters". Immun.; 37: 1261-1269. 1982.
Cook J. A.,
et al,, "Viscereal Leishmaniasis in Mice: Protective Effect
of Glucan". J. Reticuloendothel; Soc. 27: 567-573. 1980.
Cross CE,
Bancroft GJ, "Ingestion of acapsular Cryptococcus neoformans occurs
via mannose and beta-glucan receptors, resulting in cytokine
production and increased phagocytosis of the encapsulated
form." Infect Immun 63:2604-2611. 1995. Dept Clin Sci, London
Sch of Hyg and Trop Med, England.
Crueger, et
al., Biotechnology: A Textbook of Industrial Microbiology; 2nd
ed, pp. 9-58. 1989.
Czop JK, Janusz
M; "Derivativized polysaccharides with biologic activity, method
of their isolation, and uses therefor;" U.S. Patent 5057503,
Issued Oct 15, 1991. *
Czop J.K.,
Kay J., Isolation and Characterization of B-glucan Receptors on
Human Mononuclear Phagocytes. J. Exp. Medicine; V.173: 1511-1520.
1991. (Copy available) Dept of Med, Harvard Med Sch, Boston,
MA. * Quote: "...human alveolar macrophages ...possess phagocytic
receptors of comparable ligand specificity for the Beta glucans
commonly present in yeast and fungi. Pathogens such as Candida
and Aspergilli contain "yeast" glucan, cell wall components consisting
of branched homopolymers of Beta-D-glucose with 1,3 consecutive
and 1,6-crosslinked chains and prototypic of Saccharomyces cerevisiae."*
Czop J.K.,
Gurish M.F., Kadish J.l., Production and Isolation of Rabbit Anti-idiotypic
Antibodies Directed Against the Human Monocyte Receptor for Yeast
B-glucans. Journal of Immunology; 145:995-1001. 1990. Dept
of Med, Harvard Med Sch, Boston, MA. * Quote (p1): "Beta-Glucans
with 1,3 and/or 1,6 linkages are the major structural components
of yeast and fungi and are pharmacological agents in animals...The
cell wall glucans of S. cerevisiae consist of two structurally
distinct Beta-glucans: major components comprised of consecutively,
1,3-linked glucopyranosyl residues with small numbers of 1,6-linked
branches, and minor components with consecutive 1,6-linkages and
1,3-branches."
Czop, J.K.,
Valiante N.M., Janusz M.J.; "Phagocytosis of particulate activators
of the human alternative complement pathway through monocyte beta-glucan
receptors," Prog Clin Biol Res 297: 287-296; 1989. Dept of
Med, Harvard Med S, Boston, MA. * Quote (p1): "Animal studies
indicate that beta-glucans with 1,3-and/or 1,6-linkages are active
pharmacologic agents that rapidly confer protection to a normal
host against a variety of biological insults. The beta-glucan
receptors provide a mechanism by which a heightened state of host
responsiveness is initiated."
Czop J.K.,
Puglisi A.V., Miorandi D.Z., Austen K.F.; "Pertubation of beta-glucan
receptors on human neutrophils initiates phagocytosis and leukotriene
B4 production," J. Immunol 141: 3170-3176. 1988. *
Czop, Joyce
K., "The Role of Beta-Glucan Receptors on Blood and tissue
Leukocytes in Phagocytosis and metabolic Activation". Pathology
and Immunopathology Research; 5:286-296. 1986. *
Czop J.K.,
Austen K.F., A B-glucan Inhibitable Receptor on Human Monocytes:
Its Identity with the Phagocytic Receptor for Particular Activators
of the Alternative Complement Pathway. Journal of Immunology
134: 1985; 2588-2593. 1985. *
Czop J.K.,
Austen K.F.; "Properties of glycans that activate the human alternative
complement pathway and interact with the human monocyte beta-glucan
receptor," J Immunol 135: 3388-3393. 1985. *
Czop J.K.,
Austen K.F.; "A beta-glucan inhibitable receptor on human monocytes:
its identity with the phagocytic receptor for particulate activators
of the alternative complement pathway," J Immunol 134(4): 2588-2593,
Apr 1985. *
Czop J.K.,
Austen K.F.; "Generation of leukotrienes by human monocytes upon
stimulation of their beta-glucan receptor during phagocytosis,"
Proc Natl Acad Sci USA; 82: 2751-2755 1985. *
Czop J.K.,
Dadish Jl, Zepf DM and Austen KF; "Identification with monoclonal
antibodies of different regions of human plasma fibronectin, including
that which interacts with human monocyte fibronectin receptors;"
Immunology. 54:407. 1985.
Czop J.K.,
Mcgowan SE and Center DM; "Opsonin-independent phagocytosis
by human alveolar macrophages: augmentation by human plasma
fibronectin;" Am Rev Respir Dis, 125:607. 1982.
Czop J.K,
Fearon DT, and Austen KF; "Opsonin-independent phagocytosis of
activators of the alternative complement pathway by human monocytes;"
J Immunol; 120:1,132; 1978.
Damia, et
al, "Prevention of Acute Chemotherapy-Induced Deathin Mice
by Recombinate Human Interleukin 1: Protection from Hematological
and Nonhematological Toxicities", Cancer Research, vol. 52,
pp. 4082-4089.
Daum T., Rohrbach
M.S.; "Zymosan induces selective release of arachidonic acid from
rabbit alveolar macrophages via stimulation of a beta-glucan receptor,"
FEBS Lett 309: 119-122; 1992.
Deimann W,
Fahimi HD, "The Appearance of Transition Forms Between Monocytes
and Kupffer Cells in the Liver of Rats Treated with Glucan,"
J Exp Med, p883-897, Apr 1979. * Dept of Anat, U of Heidelberg,
Germany. *
Delville,
et al., entitled "Le-.beta-1, 3-Glucan et Autres Immunomodulateurs
dans L'Unfection lepresis Experimentale Chez La Souris". Acta
Leprologica; 77/76: 273-281. 1979.
De Fellipi
J. Jr., Freire C.A.R., Harbach E.t. et al; Celularidade do sangue
periferico apos o emprego da glucana, um imunostimulante de SRE.
Em pacientes septicos e em voluntarios sem infeccao; Rev Ter
Intensiva 1: 45-52; 1987.
Deslanders,
et al., "Triple-Helical Structure (1,3)-beta-D-Glucans". Macromolecules
13: 1466-1471. 1980.
"Development
& Comparative Immunology," Editorial Board, Pergamon; 1997.
Deville, et
al., "Le-Beta 1,3-Glucan et Autres Immunomodulateurs dans L'Unfection
lepresis Experimental Chez La Souris" Acta Leprologica 77/76:
273-281.; 1979.
Diluzio N.R.,
"Soluble phosphorylated glucan," U.S. Patent 487777, Issued
Oct 31, 1989.
Diluzio N.R.
(deceased), Williams D.L., Browder I.W.; Soluble phosphorylated
glucan: methods and compositions for treatment of neoplastic diseases;
U.S. Patent 4818752; 1989.
Diluzio N.R.;
Soluble phosphorylated glucan; U.S. Patent 4739046; 1988.
Diluzio N.R.
and Williams D.L., " The Roll of Glucan in the Prevention and
Modification of Microparasitic Diseases;" in Chemical Regulation
of Immunology in Veterinary Medicine, Alan R. Liss, Inc.; pp.
443-456. 1984.
Diluzio N.R.,"Immunopharmacology
of glucan: a broad-spectrum enhancer of host defense mech/anisms,"
Trends in Pharmacol. SCI., 4:344-347. 1983. Dept of Physiology,
Tulane U, New Orleans, LA. * Quote: (p347) "The broad spectrum
of immunopharmacological activities of glucan includes not only
the modification of certain bacterial, fungal, viral and parasitic
infections, but also inhibition of tumor growth."
Diluzio N.R.
Williams D.L. et al, "Comparative evaluation of the tumor inhibitory
and antibacterial activity of solubilized and particulate glucan,"
Recent Results Cancer Res 75:165-172. 1980. * Quote: "Intravenous
administration of soluble or particulate glucan resulted in significant
reduction in the growth of a syngeneic anaplastic mammary carcinoma
and melanoma B16 and enhanced survival."
Diluzio NR,
Williams DL; "Enhancement of host susceptibility to Staphylococcus
aureus infection by chronic ethanol ingestion-modification by
glucan immunostimulation," Alcohol Clin Exp Res 4(3): 254-260.
Jul 1980. * Quote: "The administration of glucan significantly
prolonged survival of S. Aureus infected control and chronic ethanol
mice."
Diluzio N.R.
and Chihara, Advances in Immunopharmacology Hadden et al., eds.,
Pergamon Press Oxford and New York, pp. 477-484. 1980.
Diluzio NR,
Williams DL, et al, "Comparative tumor-inhibitory and anti-bacterial
activity of soluble and particulate glucan," Int J Cancer,
24(6): 773-779. Dec 1979. * Quote: "...these studies demonstrate
that a soluble glucan preparation exhibits significant anti-tumor
and anti-staphylococcal activity."
Diluzio N.R.,
Kokoshis P.L.; Serum lysozyme: an index of macrophage function.
J Reticuloendothel Soc 25: 85-99, 1979.
Diluzio N.R.
and Williams D.L., "Glucan-Induced Modification of the Increases
Susceptibility of Cyclophosphamide-Treated Mice to Staphylococcus
aureus Infection". Cancer Immunol. Immunother.; 6: 73-79. 1979.
Diluzio NR,
Williams DL, "Protective effect of glucan against systemic Staphylococcus
aureus septicemia in normal and leukemic mice," Infect Immun
20(3): 804-810. Jun 1978. * Dept of Physiology, Tulane U,
New Orleans, LA. * Quote: "These data denote that glucan enhances
nonspecific resistance to S. aureus sepsis, promotes survival
during leukemic episodes, and increases survival time of leukemic
mice with experimentally induced staphylococcal infection."
Diluzio N.R.,
Williams D.L., Cook J.L., Hoffman E.O.; Protective effect of glucan
in experimentally induced Candidiasis; J Reticuloendothel Soc
53: 479-490, 1978.
Diluzio N.R.
and Kupffer, Cells and other Liver Sinusoidal Cells. Wisse
and Knook, eds., Elsevier, Amsterdam; pp. 397-406. 1977.
Diluzio N.R.,
et al., The Macrophage and Cancer, James et al., eds: Edinburgh
Univer. Med. Pres.; pp. 181-201. 1977.
Diluzio N.R.,
et al., "The Employment of Glucan and Glucan Activated Macrophages
in the Enhancement of Host Resistance to Malignancies in Experimental
Animals," in The Macrophage in Neoplasia; Academic Press,
Inc. New York; pp. 181-198. 1976.
Diluzio N.R.,
Morrow H.S.; Comparative behavior of soluble and particulated
antigens and inert colloids in reticuloendotheilial-stimulated
or depressed mice; J Reticuloendothel Soc 9: 273-287, 1971.
DiLuzio N.R.,
et al., "Evaluation of the Mechanism of Glucan-Induced Stimulation
of the Reticuloendothelial System". J. Reticuloendothelial
Soc.; Soc.7: 731-742. 1970.
DiLuzio, N.R.
and Riggi, J. Reticuloendothel, Soc.; 8: 465-473. 1970.
Di Renzo,
L., Yefenof, E., Klein E., "The Function of human NK cells is
enhanced by B-Glucan, a ligand of CR3 (CD11b/CD18)". Eur. J.
Immunol., 21:1755-1758. 1991.
Doita M, Rasmussen
LT, Seljelid R, Lipsky PE, "Effect of soluble aminated beta-1,
3-D-polyglucose on human monocytes: stimulation of cytokine and
prostaglandin E2 production but not antigen-presenting function."
J Leukoc Biol 49(4): 342-351. Apr 1991. *
Donzis B.
A.; Substantially purified beta (1,3) finely ground yeast cell
wall glucan composition with dermatological and nutritional
uses; U.S. Patent 5576015; 1996.
Donzis B.A.;
Solubilized yeast glucan; U.S. Patent 5519009; 1996.
Donzis B.A.;
Photoprotective composition containing yeast extract; U.S.
Patent 5397773; 1995.
Donzis B.A.;
Method of revitalizing skin by applying topically water insoluble
glucan; U.S. Patent 5223491; 1993.
Donzis B.A.;
Method and Composition for Treating Hyperlipemia. U.S. Patent
4,891,220; 1990.
Drovanti A.,
Bignamini A., Rovatyi A.; Therapeutic Activity of Oral Glucosamine
Sulfate in Osteoarthritis: A Placebo-controlled Double blind Investigation.
Clinical Therapeutics; 3(4): 260-272. 1980.
Duan X., Ackerly
M. et al; "Evidence for involvement of beta-glucan-binding cell
surface lectins."Cell Immunol 157: 393-402; 1994.*
Duvic B.,
Soderhall K.; "Purification and partial characterization of a
beta-1, 3-glucan-binding protein membrane receptor from blood
cells of the crayfish Pacifastacus leniusculus," Eur J. Biochem
207: 223-228; 1992.
Enhanced Healing
of Decubitus Ulcers by Topical Application of Particulate
Glucan. Tulane University School of Medicine; Research Summary.
1984.
Bisu et al,
"Studies on the Structure of Polysaccharides (Glucans and Fructans)
Produced by Cariogenic Streptococci and on an Enzyme Hydrolyzing
the Insoluble Glucan I. Structural Studies of Insoluble Glucan,
Soluble Glucan, and Fructans," Chemical Abstracts; vol. 38:pp.
374-381. 1976.
Elmets, et
al., J. Investigative Dermatol.; 79:340-345. 1967.
Elstad MR,
Parker C et al; "CD11b/CD18 integrin and a beta-glucan receptor
act in concert to induce the synthesis of platelet-activating
factor by monocytes," J Immunol 152:220-230. 1994.
Dept of Med, Veterans Affairs Medical Center, Salt Lake City,
UT. *
Ehrke, et
al., Int'l J. Immunopharm.; 5: 34-42. 1992
Engstad RE,
Robertsen B, "Recognition of yeast cell wall glucan by Atlantic
salmon (Salmo salar L.) macrophages," Dev Comp Immunol 17:319-330.
1993. *
Evans et al,
"Modification of the Bone Marrow Toxicity of Cis-Diamminedichloroplatinum
(II) in Mice ByDiethydithiocarbamate", Cancer Research; vol.
44, pp. 3686-3690. Sep 1984.
Federal Drug
Administration, "Appendix A Food Additives," Yeast extract
(Bakers) - FL/ADJ, GRAS, See Specs 184.1983. Washington
DC. http://www.fda.gov 1997.
Felippe J.,
Silva M., Maciel F.M., et al., Infection prevention in patients
with severe multiple trauma with the immunomodulator beta
(1-3) glucan 1-3 polyglucose (glucan). Surg. Gynecol Obstet.,
177: 3833-388. 1993.
Fernandez-Botran,
Vetvicka V.; "Methods in Cellular Immunology," CRC Press.
1995.
Fitzpatrick,
F.W., Dicarlo J.F., "Zymosan". Annals of the New York Academy
of Sciences; V.118, p233-262. 1964. *
Fleet. G.
H., et al., "Isolation and Composition of an Alkali-Soluble Glucan
from the Cell Walls of Saccharomyces cerevisiae," Chemical
Abstracts; 85:89819z. 1976.
Fleet. G.
H., et al.,"Isolation and Composition of an Alkali-Soluble Glucan
from the Cell Walls of Saccharomyces cerevisiae," Journal of
General Microbiology; 94:180-192. 1976.
Fornusek L.,
Vetvicka V.; "Immune System Accessory Cells," CRC Press. 1992.
Franek J,
Malina J, Kratka H, "Bacterial infection modulated by glucan:
a search for the host defense potentiation mechanisms," Folia
Microbiol (Praha) 37(2): 146-152. 1992. *
Gallin, Int.
J. Immunopharmac.; 14:173-183. 1992.
Giaimis J.,
Lombard Y., et al; "Both mannose and beta-glucan receptors are
involved in phagocytosis of unopsonized, heat-killed Saccharomyces
cerevisiae by murine macrophages," J. Leukoc Biol 54: 564-571.
1993. *
Gilcrest,
et al., J. Am. Acad. Dermatol.; 5:411-422. 1982.
Gillet et
al., "Particulate beta 1-3 Glucan and Casual Prophylaxis of
Mouse Malaria (Plasmodium berghei)". In advances in Exper.
Med. and Biology; vol 121A, Escobar and Friedman, eds. Plenum
Press, New York, pp. 307-313. 1980.
Glovsky MM,
et al,; "Effects of particulate beta-1, 3 glucan on human, rat,
and guinea pig complement activity," J. Reticuloendothel Soc.
33:401-413. 1983. * Quote: "Glucan administration is associated
with the modification of a variety of experimentally induced infectious
disease states as well as the inhibition of growth of implantable
and spontaneous tumors."
Goldman R.,
"Characteristics of the B-glucan Receptor of Murine Macrophages".
Exp.Cel. Res.; 174:481-490; 1988. *
Goldman R.,
"Induction of a beta-1, 3-D-Glucan Receptor in P388D1 Cells Treated
with Retinoic Acid of 1,25-dihydroxyvitamin D (3)," Immunology;
63:319-324. 1988.
Goodson, William,
Hohn, David, Hunt, Thomas K. and Leung, Y.K., "Augmentation of
Some Aspects of Wound Healing by a Skin Respiratory Factor".
Journal of Surgical Research; 21:125-129. 1976.
Goto H., Yuasa
K., Rylander R.; "(1-->3)-beta-D-glucan in indoor air, its
measurement and in vitro activity," Am J. Ind Med 25: 81-83.1994.
Green et al.,
"Preclinical Evaluation of WR-151327" An Orally Active Chemotherapy
Protector", Cancer Research, vol. 54, issued Aug. 1, 1992
Hagiwara K.,
Kikuch M., "Anti-virus agent." (Schlerotium glucanicum
et al). U.S. Patent 5320849. Issued June 14, 1994. *
Hall MN and
Linder P; "The Early Days of Yeast Genetics," Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, New York. 1993.
Hamuro, et
al., Immunomodulating Agents: Properties and Mechanisms, Chirgos,
eds., Marcel Dekker, Inc.; pp. 409-436. 1984.
Hara C., et
al., "A Branched (1.fwdarw.3)-beta-D-Glucan From a Water Extract
of Dictyophora indusiata FISCH," Carb. Res.; 145:237-246. 1986.
Harada, et
al., " Agricultural Biological, Growth and beta-Glucan
10C3K Production by a Mutant of Alcaligenes faecalis var. myxogenes
in Defined Medium"; vol. 30, No. 8, pp. 764-769. 1966.
Harada, et
al., " Production of a Firm, Resilient Gel-Forming Polysaccharide
by a Mutant of Alcaligenes faecalis var. myxogenes 10C3", Agr.
Biol. Chem.; vol. 30, No. 2, pp 196-198. 1966.
Hartland RP,
Emerson GW, Sullivan PA, "A secreted beta-glucan-branching enzyme
from Candida albicans," Pro R Soc Lond B Biol Sci, 246(1316):
155-160. Biochem Dept, U of Otago, Dunedin, New Zealand. Nov 1991
Hassid, W.Z.,
Joslyn, M.A., McReady, R.M., "The Molecular Constitution of an
Insoluble Polysaccharide From Yeast Saccharomyces Cerevisae";
Journal of American Chemical Society, 1941; 63:295-298. 1941.
Hofemeister,
"The beta-glucanase gene from Bacillus amyloliquefaciens shows
extensive homology with that of Bacillus subtilis," Gene;
49:177-187. 1986.
Holbrook J.A.C.,
Parker J.L.; Immunization against Leishmania donovani: glucan
as an adjuvant with killed promastigotes; Am J Trop Med Hyg
30: 762-768, 1981.
Holbrook T.W.,
et al., "Glucan-Enhanced Immunogenicity of Killed Erythrocylic
Stages of Plasmodium Benghei"; Infection and Immunity, 32,
542. 1981.
Honda S.,
et al, "Activation of the alternative pathway of complement by
an antitumor (1----3)-beta-D-glucan from Alcaligenes faecalis
var. myxogenes IFO 13140, and its lower molecular weight and carboxymethylated
derivatives,""Immunopharmacology 11:29-37. 1986. *
-
I - Back to Top
Inai et al.,
"Activation of the Alternative Complement Pathway by Water-Insoluble
Glucans of Streptococcus mutans: the Relation between Their Chemical
Structures and Activating Potencies." J. Immunol.; 117" 1256-1260.
1976.
Inamuzu T.,
Chang M.P., Makinodan T.; "Influence of Age on the Production
and Regulation of Interleukin-1 in Mice", Immunology; V.55,
p.447. 1985. *
-
J - Back to Top
Jacques, et
al., "Immunomodulator Polysaccharides". Current Concepts
in Human Immunology and Cancer Immunomodulation, Serron et al.,
eds. Elsevier Biomedical Press BV, pp. 429-438. 1982.
Jamas S.,
Easson D., Ostroff G.R., DavidsonDd; "Method for producing soluble
glucans," U.S. Patent 5633369. Issued May 27, 1997. *
Jamas S.,
Easson D., Ostroff G.R.; "Glucan Preparation," U.S. Patent
5622939. Issued April 22, 1997. *
Jamas S.,
Easson D., Ostroff G.R.;"Glucan drug delivery system and adjuvant,"
U.S.Patent 5607677. Issued March 4, 1997. *
Jamas S.,
Easson D., Ostroff G.R.;"Use of aqueous soluble glucan preparations
to stimulate platelet production." U.S. Patent 5532223.
Issued July 2, 1996. *
>Jamas
S., Easson D., Ostroff G.R.;"Use of neutral soluble glucan
preparations to stimulate platelet production." U.S. Patent
5488040. Issued January 30, 1996. *
Jamas S.,
Easson D., Ostroff G.R.;"Method for producing neutral glucans
for pharmaceutical applications," U.S. Patent 5322841.
Issued June 21, 1994. *<
Jamas, et
al., "A Novel Class of Macrophage-Activating Immunomodulators",
ACS Series, Polymeric Drugs and Delivery Systems; Chapter 5,
pp. 44-51. 1991.
Jamas, et
al., Biotech. and Bioeng., 1986; 28: 769-784. 1986.
Jamas, et
al., "In: Industrial Polysaccharides: Genic Engineering Structure/Property
Relations and Appl.", Elserier Science Publ. B.V., Amsterdam
N.C.; pp. 65-69.
James S.,
Chen Y-CJ, Von Der Osten C.H., et al., "Spectral analysis of glucan
produced by wild-type and mutant Saccharomyces cerevesiae".
Carbohydr. Polym., 13:207-219. 1990.
Janusz M.J.,
Austen K.F., Czop J.K.; "Isolation of a Yeast Heptaglucoside that
Inhibits Monocyte Phagocytosis of Zymosan Particles". The Journal
of Immunology; 142:959-965. 1989. Dept of Med, Harvard Med Sch,
Boston, MA. * Quote: "Beta-Glucans with 1, 3-and 1, 6 glycosidic
linkages are the major structural components of yeast and fungal
cell walls and are active pharmacologic agents in host defense
systems of plants and animals.... The administration of particulate
glucans from S. cerevisiae to laboratory animals induces host
resistance to a variety of lethal pathogens by mechanisms involving
macrophage stimulation. In vitro studies reveal that bone
marrow-derived mouse macrophages and human peripheral blood monocytes
possess Beta-glucan receptors that mediate phagocytosis of glucan
particles and induce release of proinflammatory mediators..."
Janusz M.J.,
Austen K.F., Czop J.K.; Phagocytosis of Heat-killed Blastophores
of Candida Albicans by Human Monocyte B-glucan Receptors. Immunology;
65:181-185. 1988. *
Janusz M.J.,
Austen K.F., Czop J.K.; "Lysosomal enzyme release from human monocytes
by particulate activators is mediated by beta-glucan inhibitable
receptors," J. Immunol 138: 3897-3901. 1987. *
Janusz M.J.,
et al, "Isolation of Soluble Yeast beta-Glucan that Inhibit Human
Monocyte Phagocytosis Mediated by beta-Glucan Receptors," L.
Immunol; 137:3270-3276. 1986. *
Jiang B.,
Sheraton J., et al; "CWH41 encodes a novel endoplasmic reticulum
membrane N-glycoprotein involved in beta 1, 6-glucan assembly,"
J. Bacteriol 178: 1162-1171. 1996.
Jones EW,
Broach JR and Pringle JR. ;"The Molecular and Cellular Biology
of the Yeast Saccharomyces cerevisiae;" Gene Expression; Cold
Springs Harbor Laboratory Press, Cold Spring Harbor, New York.
1992.
Jorgensen
J.B., Robertsen B.; "Yeast beta-glucan stimulates respiratory
burst activity of Atlantic salmon (Salmo salar L.) macrophages,"
Dev Comp Immunol 19: 43-57. 1995. *
Jorgensen
J.B., "Quantification of high molecular weight (1-3)(1-4)-beta-D-glucan
using calcofluor complex formation and flow injection analysis.
I. Analytical principle and its standardization," Carlsberg
Res. Commun. (1988); 53:277-285. 1988.
-
K - Back to Top
Kadish, J.L.,
Choi C.C., Czop J.K.; "Phagocytosis of unopsonized zymosan particles
by trypsin-sensitive and beta-glucan-inhibitable receptors on
bone marrow-derived murine macrophages," Immunol Res 5: 129-138.
1986. *
Kallin E.,
et al, "New Derivatization and Separation Procedures for Reducing
Oligosaccharides", Glycoconjugate J; pp. 311-319. Sep 1984.
Kan V.L.,
Bennett J.E.; "Beta 1, 4-oligoglucosides inhibit the binding
of Aspergillus fumigatus conidia to human monocytes," J
Infect Dis 163: 1154-1156. 1991.
Kaplan J.;
"Acceleration of Wound Healing by a Live Yeast Cell Derivative".
Archives and Surgery", Sep. 1984; 119:1005-1008. 1984.
Kapteyn J.C.,
Montijn R.C., et al; "Retention of Saccharomyces cerevisiae cell
wall proteins through a phosphodiester-linked beta-1, 3/beta-1,
6-glucan heteropolymer," Glycobiology 6: 337-345. 1996.
* Institute of Molecular Cell Biology, U of Amsterdam, The Netherlands.
Kapteyn J.C.,
Montijn R.C., et al; "Covalent association of beta-1, 3-glucan
with beta-1, 6-glucosylated mannoprotein in cell walls of Candida
albicans," J Bacteriol 177: 3788-3792. 1995. *
Kapteyn J.C.,
Montijn R.C., et al; "Glucosylation of cell wall proteins in regenerating
spheroplasts of Candida albicans," FEMS Microbiol Letter 128:
271-277. 1995. *
Kapteyn J.C.,
Montijn R.C., et al; "Identification of beta-1, 6-glucosylated
cell wall proteins in yeast and hyphal forms of Candida albicans,"
Euro J Cell Biol 65: 402-407. 1994. *
Kasahara S.,
Ben Inoue S., Mio T., Yamada T., Nakajima T., Ichishima E., Furuichi
Y., Yamada H., "Involvement of cell wall beta (1-3) glucan-glucan
in the action of HM-1 killer toxin", FEBS Lett 348 (1): 27-32.
1994.
Kasai, S.,
Fujimoto S., Nitta K., Baba H., Kunimoto T., "Antitumor activity
of polymorphonuclear leukocytes activated by a B-1, 3-D-glucan".
J. Pharmacobiodyn. 14:519-525. Medline.
Kashkina Ma.,
Freidlin IS., "Macrophage activation by polysaccharides from yeast-like
fungi", Biull Eskp Biol. Med 89 (4): 439-441. 1980.
Kay J., Czop
J.K., ""Enhancement of human monocyte beta-glucan receptors by
glucocorticoids," Immunology 81: 96-102. 1994. *
Kiistala,
et al., J. Investigative Dermatol.; 48:466-477. 1967.
Kimura, et
aL., "In Vitro Activation of Human Adherent Cells by a Glucan,
Schizophyllan". J. Reticuloendothel.; Soc. 34: 1-11. 1983.
Kohl, et al.,
"Inhibition of Human Monocyte-Macrophage and Lymphocyte Cytotoxicity
to Herpes simplex Cells by Glucan". J. Immunol. Methods; 29:
361-368. 1979. * Quote: "Particulate, cell-associated glucan
irreversibly inhibited MP antibody-dependent cellular cytotoxicity
(ADCC)."
Kokoshis P.L.,
Williams D.L., Cook J.A., Di Luzio N.R.; Increased resistance
to Staphylococcus aureus infection and enhancement in serum lysozyme
activity by glucan. Science 199: 1340-1342, 1978. * Quote:
"These studies indicate that glucan confers an enhanced state
of host defense against bacterial infections."
Konopski Z.,
Seljelid R., Eskeland T.; "Interferon-gamma inhibits endocytosis
of soluble animated beta-1, 3-D-glucan and neutral red in mouse
peritoneal macrophages," J Interferon Cytokine Res 15(7):
597-603. Jul 1995. * Dept of Exper Path and Anat, U of Tromso,
Norway.
Konopski Z.,
Seljelid R., Eskeland T.; "IFN-gamma inhibits internalization
of soluble aminated beta-1-3-D-glucan by macrophages and thereby
down-regulates the glucan induced release of TNF-alpha and IL-1
beta," Scand J. Immunol 40: 57-63. 1994. *
Konopski Z.,
Seljelid R., Eskeland T.; "A novel immunomodulator soluble aminated
beta-1, 3-D-glucan: binding characteristics to mouse peritoneal
macrophages," Biochem Biophys Acta 1221(1): 61-65. Mar 1994. *
Konopski Z.,
Seljelid R., Eskeland T.; "Cytokines and PGE2 modulate the phagocytic
function of the beta-glucan receptor in macrophages," Scand
J. Immunol 37: 587-592. 1993. *
Konopski,
Z., et al., "Phagocytosis of beta-1, 3-D-Glucan-Derivatized Microbeads
by Mouse Peritoneal Macrophages Involves Three Different Receptors,"
Scand. J. Immunol.; 33:297-306. 1991. *
Kopecka M.;
"Electron microscopic study of purified polysaccharide components
glucans and mannan of the cell walls in the yeast Saccharomyces
cerevisiae," J Basic Microbiol 25: 161-174. 1985. *
Kopecka M.,
et al., The Journal of Cell Biology; 62:66-76. 1974.
-
L - Back to Top
Lahnborg G.,
Hedstrom K.G., Nord C.E.; "The Effect of Glucan - A Host Resistance
Activator and Ampicillin on Experimental Intraabdominal Sepsis".
Journal of Reticuloendothelial Society. 32: 347-353. 1982. *
Quote: "It is concluded that glucan, in combination with Ampicillin,
has a significant effect on the survival rate of rats with induced
peritonitis, probably by enhancing the activities of the reticuloendothelial
system, an important part of the total host resistance."
Lahnborg,
et al., "Glucan-Induced Enhancement of Host Resistance in Experimental
Intraabdominal Sepsis". Eur. Surg. Res.; 401-408. 1982.
*
Larm O., Seljelid
R., "Water-soluble aminated beta-1, 3-bount D-glucan and composition
containing same," U.S. Patent 4707471; Issued Nov 17,
1987.
Leibovich
S.J., et al., "Promotion of Wound Repair in Mice by Application
of Glucan". J. Reticuloendothel, Soc. 27: 1-11. 1980.
Lejeune FJ.,
Vercammen-Granfjean A., Mendes Da Costa P., Bron D., Defleur V.,
"Suppressor cell induction and reticuloendothelial cells activation
produced in the mouse by beta(1-3)glucan 1-3 glucan", Adv.
Exp. Med. Biol. 121 (A): 235-244. 1979. *
Lotzova and
Gutterman, "Effect of Glucan on Natural Killer (NK) Cells:
Further Comparison between NK Cell and Bone Marrow Effector
Cell Activities". J. Immunol., 123: 607-611. 1979.
-
M - Back to Top
Mahauthaman
R, Howell CJ, Spur BW, Youlten LJ, Clark TJ, Lessof MH and Lee
TH; "The generation and cellular distribution of leukotriene C4
in human eosinophils stimulated by unopsonized zymosan and glucan
particles;" J Allergy Clin Immunol 81:696. 1988.
Manners, D.J.,
Masson, A.J. & Patterson, J.C.: "Heterogeneity of Glucan Preparations
from the Walls of Various Yeasts". J. of Gen Micro.; 411-417.
1974.
Manners, D.J.,
et al., "The Structure of a beta- (1.fwdarw.3)-D-Glucan from Yeast
Cell Walls," BiochemJ.; 135: 19-30. 1973.
Mansell P.W.A.,
Rowden G., Hammer C.; Clinical experiences with the use of glucan.
Chirigos MA, ed.; Immune Modulation and Control of Neoplasia
by Adjuvant Therapy. Raven Press, New York 255-280; 1978.
Mansell P.W.A.,
Ichinose H., Reed RJ., Krements E.T., McNamee R.B., Di Luzio N.R.;
Macrophage-medicated Destruction of Human Malignant Cells in
Vivo. Journal of National Cancer Institute; 54: 571-580. 1975.
Mansell P.W.A.
and Diluzio N.R., Macrophage in Neoplasia Fink, ed. Academic
Press, New York, pp. 227-243. 1976.
Mansell P.W.A.,
et al., Activation of the Alternative Complement Pathway by Water-Insoluble
Glucans of Streptococcus mutans: the Relation Between Their
Chemical Structures and Activating Potencies". Macrophage-Mediated
Destruction of Human Malignant Cells in Vitro; Inai et al., J.
Immunol (1976); 1256-1260. 1976
Mansell P.W.A.,
Ichinose H., Reed R.J., Krements E.T., McNamee R.B., Di Luzio
N.R.; "Macrophage-mediated Destruction of Human Malignant Cells
in Vitro". Journal of National Cancer Institute; 54: 571-580.
1975. Quote: "The initial 9 patients studied had malignant
carcinoma of the breast. Control and experimental lesions
were injected; subsequently biopsies were performed at varying
intervals for histologic evaluation. Always when glucan or glucan
and RF fractions were administered intra-lesionally; the size
of the lesion was strikingly reduced in as short a period as 5
days. ...In small lesions, resolution was complete, whereas in
large lesions, resolutions was partial."
Marchetti
M., Pisani S., Pietropaolo V., Seganti L., Nicoletti R., Degener
A., Orsi N., "Antiviral effect of a polysaccharide from Sclerotium
glucanicum towards herpes simplex virus type 1 infection",
Planta. Med. 62 (4): 303-307. 1996.
Marrow S.H.,
Di Luzio N.R., The fate of foreign red cells in mice with altered
reticuloendothelial function. Proc Soc Exp Biol Med 119: 647-652,
1965.
Maruyama,
K., Yamamoto, K., Nagura, S.; "Method for purifying polysaccharides,"
U.S. Patent 5602241; Issued February 11, 1997.
Mashiba, et
Al., "In Vitro Activation of Human Adherent Cells by a Glucan
Schlzophillan". Japan J. Exp. Med; 53: 195-198. 1983.
McCleary,
"Soluble, dye-labeled polysaccharides for the assay of endohyrolases,"
Methods Enzymol; 160:74-86. 1988.
Meira, D.A.,
et al; The Use of Glucan as Immunostimulant in the Treatment of
Paracoccidioidomycosis; Am J. Trop Med Hyg 55(5), 496-503;
1996. Dept of Trop Dis, Dept of Microbio, State U of Sao Paulo,
Brazil. Quote: "...glucan enhances the immune response
through stimulation of macrophages by increasing their number,
size, and function, stimulates secretion of lysozyme and TNF by
activated macrophages, increases the phagocytosis of antigens,
activates the formation of granulocyte and monocyte colonies,
and factors increased activity of T and B lymphocytes, as well
as complement activation. "
Mio T. et
al, "Isolation of the Candida albicans homologs of Saccharomyces
cerevisiae KRE6 and SKN1: expression and physiological function,"
J Bacteriol 179(7): 2363-2372, Nippon Roche Res Ctr, Kamakura,
Japan. Apr 1977.
Mitsutake
K, et al; "Enolase Antigen, Mannan Antigen, Cand-Tec Antigen,
and (-Glucan in Patients with Candidemia," J of Clin MicroB,
p1918-1921, 1137; 1996. Copyrighted. Sec Dept of Int Med, Nagasaki
U Sch of Med, Nagasaki, Japan. *
Miura N.N.,
Ohno N., Adachi Y., Yadomae T.; "Characterization of sodium hypochlorite
degradation of Beta-glucan in relation to its metabolism in vivo,"
Chem Pharm Bulletin (Tokyo) 44: 2137-2141. 1996. *
Miyazaki,
T., et al., "Structural Examination of Antitumor, Water-Soluble
Glucans from Grifora umbrellata by Use of Four Types of Glucanase,"
Carbohydrate Research; 65:235-243. 1978.
Modification
of Experimental Viral Hepatitis by Glucan Induced Macrophage Activation".
Elesevier/North Holland Biomedical Press; pp. 363-368. 1980.
Morikawa K.,
Takeda, M., Yamazaki, M., and Mizuno D., "Induction of tumoricidal
activity of polymorphonuclear leukocytes by a linear B-1, 3-D-glucan
and other immunomodulators in murine cells". Cancer Res., 45:
1496-1501. (Medline).
Montijn RC
et al, "Glucomannoproteins in the cell wall of Saccharomyces cerevisiae
contain a novel type of carbohydrate side chain," J Biol Chem,
269(30): 19338-19342: Inst of Molecular C Biol, U of Amsterdam,
The Netherlands. Jul 1994.
Mortimer RK,
Contopoulou CR, King JS, "Genetic and physical maps of Saccharomyces
cerevisiae," Edition 11. Yeast 8:817-902. 1992.
Muller A.,
Rice P.J., Ensley H.E., et al; "Receptor binding and internalization
of a water-soluble (1-->3)-beta-D-glucan biologic response
modifier in two monocyte/macrophage cell lines," J.Immunol
156: 3418-3425. 1996. *
Murphy, "The
DNA sequence of the gene and genetic control sites for the execration
B. subtilis enzyme beta-glucanase," Nucleic Acids Res.; 12:5355-5367.
1984.
Muto S., Vetvicka
V., Ross G.D.; "CR3 expressed by cytotoxic T cells and NK cells
is upregulated in a manner similar to neutrophils following stimulation
with various activating agents," J Clin Immunol 13: 175-184.
1993.
-
N - Back to Top
Nakajima T
and Ballou CE; "Structure of the linkage region between the polysaccharide
and protein parts of Saccharomyces cerevisiae mannan." J Biol
Chem. 249:7685. 1974.
Nemoto J.,
Ohno N., et al; Analysis of cytokine in mBNAs induced by the administration
of a highly branched (1-3)-B-D-glucan. OL-2. Biol. Pharm Bull.
17:948-54; 1994.
Niki L., Allbright
L., "Composition and method to enhance the efficacy of a fish
vaccine and to stimulate the immune system of fish." (A
method to stimulate the immune system by a beta (1-3) glucan having
a beta (1-3) glucan-1, 3-linked main chain with beta (1-3) glucan-1,
6-linked single glucose side chains); U.S. Patent 5189028.
Issued February 23, 1993.
Niskanen E.O.,
Burgaleta C., Cline M.J., Goide D.W.; Effect of glucan, a macrophage
activator, on murine haemopoietic cell proliferation in diffusion
chambers in mice; Cancer Res 38: 1406-1409, 1978.
Norton MD,
JA [Prof. of Surg, Chief of Endocrine and Oncologic Surgery];
"Editorial: Annals of Surgery," Washington University School
of Medicine, Nov 1994. Quote: "In a prospective, randomized
double-blind study, [Babineau, et.al.] demonstrate that the preoperative
administration of PGG-glucan, a substance derived from yeast that
increases the microbial killing activity of leukocytes, can decrease
infectious complications in patients undergoing major surgical
procedures...the preliminary results are positive and should be
interpreted as good news."
Nuyen and
Stadtsbaeder, "Comparative Biological and Antitoxoplasmic Effects
of Polysaccharides, In Vitro". In Advances in Exper. Med. and
Biology, vol. 121A Escobar and Friedman, eds. Plenum Press,
New York; pp. 255-266. 1980.
- O - Back to Top
Ohno N., Terui
T., Chiba N., Kurachi K., Adachi Y., Yadomae T.; "Resistance of
highly branched (1-->3)-beta-D-glucans to formolysis," Chem
Pharm Bulletin (Tokyo) 43: 1057-1060. 1995. *
Olson E.J.,
Standing J.E, et al; "Fungal beta-glucan interacts with vitronectin
and stimulates tumor necrosis factor alpha release from macrophages,"
Infect Immun 64: 3548-3554. 1996.
Onderdonk,
AB., et al., "Anti-Infective Effect of Poly-.beta.1-6 -Glucotrisyl-beta
1-3-Glucopyranose Glucan In Vivo," Infec. Immun.; 60:1642-1647.
1992. Dept of Pathology, Channing Lab, Brigham and Women's Hospital,
Boston, MA. * Quote: "Mice challenged with Escherichia
coli or Staphylococcus aureus were protected against lethal peritonitis
by the intravenous administration of 10 micrograms of poly-beta
1-6-glucotriosyl-beta 1-3-glucopyranose (PGG) glucan per animal
4 to 6 h prior to bacterial challenge."
Ostroff, G.R.;
"Inhibition of infection-stimulated oral tissue destruction by
beta (1-3) glucan (1,3)-glucan," U.S. Patent 5622940. Issued
April 22, 1997.>
Ostroff, et
al., "Manipulation of Yeast Glucan Structure: Molecular Weight,
Branch Frequency and Branch Length". The Fermentor, 9(12)L51,
American Cancer Society; Abstract No. 19.; Aug 1989.
-
P - Back to Top
Patchen M.L.
[V Chrm, Dept of Surg, U of Washington], et al, "Mast Cell Growth
Factor (c-kit Ligand) in Combination with Granulocyte-Macrophage
Colony-Stimulating Factor and Interleulin-3: in vivo Hemopoietic
effects in Irradiated Ice compared to in vivo effects", Biotherapy;
vol. 7. pp. 13-26. 1994.
Patchen M.L.,
et al, "Effects of Combined Administration of Interleukin-6 and
Granulocyte Colony-Stimulating Factor on Recovery from Radiation-Induced
Hemopoietic Aplasia", Experimental Hematology; vol. 21, see
pp. 338-344. 1993.
Patchen M.L.,
D'Alesandro M.M., Brook I., Blakely W.F. Mcvittie T.J.; "Glucan:
Mechanisms Involved in Its 'Radioprotective' Effect". J Leuc
Biol.; 42:95-105. 1987.
Pachen M.L.
Macvittie TJ, "Comparative effects of soluble and particulate
glucans on survival in irradiated mice," J Biol Response Mod
5(1): 45-60. Feb 1986. * Experimental Hematology Dept, Armed
Forces Radiobiology Research Inst, Bethesda, MD. Quote: "Both
glucan-P and glucan-F enhanced the recovery of peripheral blood
white cell numbers, platelet numbers, and hematocrit values. In
addition, both agents increased endogenous pluripotent hemopoietic
stem cell numbers in sublethally irradiated mice."
Pachen M.L.,
Macvittie T.J.; "Stimulated Hemopeiesis and Enhanced Survival
Following Glucan Treatment in Sublethally and Lethally Irradiated
Mice". Int. J. Immunopharmac; 7: 923-932. 1985.
Patchen M.L.,
et al., J. Biol. Res. Mod.; 3:627-633. 1984. Patchen M.L.,
McVittie T.J.; Temporal Response of Murine Pluripotent Stem Cells
and Myeloid and Erythroid Progenitor Cells to Low-dose Glucan
Treatment. Acta Hemat; 70:281-288. 1983. Experimental Hematology
Dept, Armed Forces Radiobiology Research Insti, Bethesda, MD.
* Quote: "Clearly, there are numerous possible uses for an
agent such as glucan, which is a potent stimulator of hemopoietic
activity. Currently, we [U.S. Armed Services] are using glucan
to enhance hemopoietic proliferation in conjunction with hemopoietic
injury induced by radiation."
Patchen, M.L.,
Survey of Immunological Research; 2: 237-242. 1983.
Patchen, M.L.,
Lotzova E.; Modulation of murine hemopoiesis by glucan; Exp
Hermatol 8: 409-422, 1980.
Patent Abstracts
of Japan; "Production of beta-1, 3-glucan" (24 May 1989) vol.
13, No. 224, (C-599) {3572) & Japanese Patent Application
No. 137297; 7 Feb. 1989.
Patent Abstracts
of Japan; "Production of beta-1, 3-glucan by cell of genus Euglena,"
15 Aug 1988, vol. 12, No. 299, (C-520) {3146} & Japanese Patent
Application No. 6371192, 31 Mar. 1988.
Paulik S.,
Svrcek S., et al; "The effect of fungal and yeast glucan and levamisole
on the level of the cellular immune response in vivo and leukocyte
phagocytic activity in mice," Vet Med (Praha) 37: 675-685.
1992. *
Petre, et
al., "Purification and properties of an endo-beta-1, 4-glucanase
from Clostridium thermocellum," (abst.) 7-Enzymes, (1981);
95:145879q, Biochemie; 63:629-639. 1981.
Popisil, et
al., "Glucan Induced Hemopoietic Recovery in Gamma-Irradiated
Mice". Experientia; 38: 1232-1234. 1982.
Poutsiaka
D.D., et al, "Cross-linking of the beta-glucan receptor on human
monocytes results in interleukin-1 receptor antagonist but not
interleukin-1 production," Blood 82: 3695-3700; 1993. Dept
of Med, New England Med Ctr, Boston, MA. Quote: "Because of
their differential effects on cytokine production, beta-glucans
may be used to therapeutic advantage in the diseases in which
IL-1 is implicated."*
Pretus, H.
A., et al., "Isolation, Physicochemical Characterization and Preclinical
Efficiency Evaluation of Soluble Scleroglucan," The Journal
of Pharmacology and Experimental Therapeutics, 500-510. 1991.
Price G.B.,
Makinodan T.; "Immunologic Deficiencies in Senescence". The
Journal of Immunology; 108: 403-312. 1972.
Proctor, et
al., "Development of a Bioassay for Anti-Tumor Activity of the
Reticuloendoethelial Stimulant Class: Reproducibility of the Bioassay".
J. Immunopharmacol.; 3: 385-395. 1981-1982. * Quote: "Intravenously
administered DiLuzio glucan...caused dose dependent increases
in the tumor cell loss from the lungs of ...mice challenged respectively
with intravenous 125IuDR labeled B16 or T 1699 mammary carcinoma
cells."
Proctor J.W.,
Stiteler R.D., Yamamura Y., Mansell P.W., Winters R., "Effect
of glucan and other adjuvants on the clearance of radiolabeled
tumor cells from mouse lungs", Cancer Treat. Rep. ^2 (11):
1873-1880. (1978).
Proctor and
Yamamura; "Letters to the Editor: Effectiveness of Glucan in the
Treatment of Human Neoplasia". J. Nat'l Cancer Inst.; 61: 1179-1180.
1978.
-
Q -
-
R - Back to Top
Raa J., Roerstad
G., Engstad R., Robertsen B., "The Use of Immunostimulants to
Increase Resistance of Aquatic Organisms to Microbial Infection".
J. Dermatol. Surg. Oncol., (1989) 15:1199-1202. 1989.
Radioprotective
Effect of Oral Administration of Beta (1-3) glucan" Research
Report, Armed Forces Radiobiology Research Institute, Bethesda,
MD 1989.
Rasmussen,
LT, Konopski Z, Oian P, Seljelid R; "Killing of Escherichia
coli by mononuclear phagocytes and neutrophils stimulated
in vitro with beta-1, 3-D-polyglucose derivatives," Microbiol
Immunol 36(11):1173-1188. 1992. * Inst of Med Bio, U of Tromso,
Norway.
Rasmussen,
LT and Seljelid, R.: "Novel Immunomodulators With Pronounced In
Vitro Effects Caused by Stimulation of Cytokine Release", Journal
of Cellular Biochemistry; 46:60-68. 1991. * Inst of Med Bio,
U of Tromso, Norway. Quote: "Beta-1, 3-D-polyglucose derivatives
protect mice against otherwise lethal bacterial infections."
Rasmussen
LT, Seljelid R, "Dynamics of blood components and peritoneal
fluid during treatment of murine E. coli sepsis with beta-1, 3-D-polyglucose
derivatives. I. Cells.," Scand J Immunol 32(4): 321-331.
Oct 1990. *
Rasmussen
LT, Seljelid R, "Dynamics of blood components and peritoneal fluid
during treatment of murine E. coli sepsis with beta-1,
3-D-polyglucose derivatives. II. Interleukin 1, tumor necrosis
factor, prostaglandin E2 and leukotriene B4," Scand J Immunol
32(4): 333-340. Oct 1990. *
Rasmussen
LT, Seljelid R, "The modulatory effect of lipoproteins on the
release of interleukin 1 by human peritoneal macrophages stimulated
with beta-1, 3-D-polyglucose derivatives." Apr 1989. *
Rasmussen
LT, Seljelid R, "Production of prostaglandin E2 and interleukin
1 by mouse peritoneal macrophages stimulated with beta-1, 3-D-glucan
derivatized plastic beads," Scand J Immunol 26(6): 731-736.
Dec 1987. *
Rasmussen,
LT, Fandrem. Jr., and Seljelid R., "Dynamics of Blood Components
and Peritoneal Fluid During Treatment of Murine E. Coli Sepsis
with beta-1, 3-D-polyglucose Derivatives"; Scand. J 63:73-80
Immunol. 1985.
Ray P.M.;
"Cooperative action of beta-glucan synthetase..." Biochim Biophys
Acta 629: 431-444. 1980.
Reynolds J.A.,
et al., "Glucan-Induced Enhancement of Host Resistance to Selected
Infectious Diseases", Infection and Immunity; 30, 51. 1980.
*
Riggi and
Diluzio N.R.; "Hepatic Function during Reticuloendothelial Hyperfunction
and Hyperplasia." Nature (1962) 193: 1292-1294. 1962.
Riggi and
Diluzio N.R.; Am. J. Physiol.; 200:297-300. 1961.
Rios-Hernandez
M., Dos-Santos N.J., Silvia-Cardosa, Belle-Garciga J.l., Peddrosa
M., "Immunopharmacological studies of beta (1-3) glucan-1, 3-glucan",
Arch. Med. Res. 25 (2): 179-180. 1994. *
Robertsen
B., Engstad R.E., Jorgensen J.B.; "Beta (1-3) glucan-glucans as
Immunostimulants in Fish". Modulators of Fish Immune Responses;
V.1.; 1994.
Roemer T,
et al; "Characterization of the yeast (1-->6)-beta-glucan biosynthetic
components, Kre6p andSkn1p, and genetic interactions between the
PKC1 pathway and the extracellular matrix assembly," J Cell
Bio 127(2): 567-579. Oct 1994. *
Roemer T,
Delaney S, Bussey H; "SKN1 and KRE6 define a pair of functional
homologs encoding putative membrane proteins involved in beta-glucan
synthesis," Mol Cell Biol 13(7): 4039-4048. Biol Dept, McGill
U, Montreal, Quebec, Canada, Jul 1993. *
Roemer T,
Bussey H; "Yeast beta-glucan synthesis: KRE6 encodes a predicted
type II membrane protein required for glucan synthesis in vitro
and for glucan synthase activity in vitro," Proc Natl Acad
Sci USA, 88(24): 11295-11299. Dec 1991.
Roos D, Van
Schaik MLF, de Boer M and Daha MR; "Interaction between neutrophils
and zymosan particles: the role of opsonin and divalent cations;"
J Immunol 126:433. 1981.
Ross G.D.,
Vetvicka V.; "CR3: A phagocyte and NK cell membrane receptor with
multiple ligand specificities and functions," Clin Exp Immunol
92: 181-184. 1993.
Ross, G.D.,
Cain J.A., Myones B.L. et al; "Specificity of membrane complement
receptor ont type three (CR3) for beta-glucans," Complement
4: 61-74. 1987.
Ross P., Mayer
R. Benziman M.; "Cellulose biosynthesis and function in bacteria,"
Microbiol Rev 55: 35-58. 1991.
-
S - Back to Top
Sakata, T.,
von Englehardt, W.; vol. 45, No. 174, pp. 58835-58836. 1980.
Sakurai,
Int. J. Immunopharmac., 1992; 14:821-830.
Sakurai,,
Int. J. Immunopharmac., 1990; 12:675-684.
Sandula J.,
Machova E., Hribalova V.; "Mitogenic activity of particulate yeast
beta- (1-->3)-D-glucan and its water soluble derivatives,"
Int J Biol Macromol 17: 323-326. 1995. *
Sandula, et
al., Folia Microbiological; 21(3), p. 188. 1976.
Sanjuan R.,
Zueco J, Stock R, Font De Mora J, Sentandreu R; "Identification
of glucan-mannoprotein complexes in the cell wall of Candida albicans
using a monoclonal antibody that reacts with a (1,6)-beta-glucan
epitope," Microbiology, 141(Pt 7): 1545-1551; Dept de Microbiol,
Facultat de Farmacia, U. de Valencia, Burjassot, Spain. Jul 1995.
Sarko, et
al.; "Multiple-Helical Glucans". Biochem. Soc. Trans.; 11:
139-142. 1983.
Sarko, et
al., "Antitumor Activity of Tetrahydro-2-furnal-antetrahydro-2-pyranyl-Glucans
Obtained by Chemical Modification of (1,3)-beta D-Glucan from
Alcaligenes faecalis var. myxogenes IFO 13140 and its Lower Molecular
Weight Glucans" Cancer Treat Rep. (1983) Rep. 67:275-280. 1983.
Sarko, et
al., "Effect of Serum from Mice Treated with Antitumor Polysaccharide
on Expression of Cytotoxicity by Mouse Peritoneal Macrophages".
J. Pharm. Dyn.; 5: 1012-1216. 1982.
Sasaki, et
al., "Dependence on Chain Length of Antitumor Activity of (1,3)-beta-D-Glucan
from Alcaligenes faecalis var. myxogenes IFO13140, and its Acid-degraded
Products". Cancer Res; 38: 379-383. 1978.
Satoh, et
al., "Elevation of Colony Stimulating Factors in Mouse Serum after
Injection of PSK, an Antitumor Polysaccharide." J. Pharm. Dyn.;
5: 818-828. 1982.
Schimanski
D.; "Cosmetic agent containing natural yeast cell contents," U.S.
Patent 4540571; Issued Sep 10, 1985.
Schultz, et
al., in "Immune Modulation and Control of Neoplasia by Adjuvant
Therapy", Chirigos, ed., Raven Press, New York; pp. 241-248.
1978.
Schultz, et
al., "Association of Macrophage Activation with Anti-tumor Activity
by Synthetic and Biologic Agents". Cancer Res.; 37:3338-43. 1977.
Schwarz, et
al., "Isolation of a Clostridium thermocellum gene encoding a
thermostable beta-1, 3-glucanase (laminarinase),"Chemical Abstracts,
(1988); 108:217067k, Biotechnology letters; 10(4): 225-230. 1988.
Schwarz, et
al., "Association of Macrophage Activation with Anti-tumor Activity
by Synthetic and Biologic Agents". Cancer Res.; 37: 3338-3343.
1977
Seljelid R,
Busund LT, "The biology of macrophages: II. Inflammation and tumors,"
Eur J Haematol 52(1): 1-12. Jan 1994. * Dept of Exp Pathol,
Inst of Med Biol, U of Tromso, Norway.
Seljelid R,
Eskeland T, "The biology of macrophages: I. General principles
and properties," Eur J Haematol 51(5): 267-275. Nov 1993. *
Seljelid R,
et al, "Evidence that tumor necrosis induced by aminated beta
1-3D polyglucose is mediated by a concerted action of local and
systemic cytokines," Scand J Immuno 30(6): 687-694. Dec 1989.
* Quote: "Aminated beta 1-3D polyglucose (AG) causes regression
of Meth A sarcoma in syngeneic mice when injected systemically
on day 7 after tumor inoculation. AG does not concentrate in the
tumor, but distributes throughout the body. AG treatment causes
release of large amounts of interleukin 1 (IL-1) both in vivo
[in the body] and in macrophage cultures in vitro [out of body]."
Seljelid R,
"Tumor regression after treatment with aminated beta 1-3D polyglucose
is initiated by circulatory failure," Scand J Immunol 29(2):
181-192; Feb 1989. *
Seljelid R,
Macrophage Activation. Scand. J. Rheumatology; Suppl. 76:67-72;
1988.
Seljelid R,
"The rediscovery of the macrophage," APMIS Suppl 2:215-223.
1988. *
Seljelid R.,
ET AL., "The protective effect of beta 1-3D-glucan-derivatized
plastic beads against Escherichia coli infection in mice,"
Scand J. Immuno 25(1): 55-60. Jan 1987. * Quote: "Pretreatment
with beta-1, 3-D-glucan-derivatized plastic beads conferred strong
protection against Escherichia coli infection in mice."
Seljelid R,
"A water-soluble aminated beta 1-3D-glucan derivative causes regression
of solid tumors in mice," Biosci Rep 6(9): 845-851. Sep 1986.
* Quote: "When water-soluble aminated beta 1, 3-D-glucan
(AG) was injected intravenously or intraperitoneally on day 7
of tumor growth, the tumors underwent complete regression."
Seljelid R.,
et al., "In vivo activation of mouse macrophages with beta-1,
3-D-glucan-derivatized plastic beads," Scand J Immunol 21(6):
601-605. Jun 1985. *
Seljelid R.,et
al., "A Soluble beta-1, 3-Glucan Derivative Potentiates the Cytostatic
and Cytolytic Capacity of Mouse Peritoneal Macrophages in Vitro".
Immunopharmacol; 7: 69-73. 1984. *
Seljelid R.,
et al., Exper. Cell Res.; 131: 121-129. 1981.
Serron, et
al., "Immunomodulators Polysaccharides," Jacques, in Current Concepts
in Human Immunology and Cancer Immunomodulation, Eds., Elesevier
Biomedical Press BV.; pp. 429-438. 1982.
Shandula I.,
Kogan G., Masler L.; "Structure and various characteristics of
yeast beta-D-glucans," Vopr Med Khim 36: 39-42. 1990.
Sherwood.
ER, et al., "Soluble Glucan and Lymphokine-activated Killer (LAK)
Cells in the Therapy of Experimental Hepatic Metastases,"
Chemical Abstracts; 108:179752V. 1988.
Sherwood.
ER, et al., "Enhancement of Interleukin-1 and Interleukin-2 Production
by Soluble Glucan," International Journal of Immunopharmacology.;
9:(3):261-267. 1987.
Shibata
Y., "Enzymatic hydrolysis of glucans containing beta-1, 3-and
beta-1, 6-linkages. 3. Gibberella beta-1, 6-glucan 6-glucanohydrolase
operative in the selective hydrolysis of beta-1, 3-glucosidic
linkages in Eisemia laminaran," J. Biochem (Tokyo) 75: 85-92.
1974.
Shiota M.,
Nakajima T., Satoh A., Shida M., Matsuda K.; "Comparison of beta-glucan
structures in a cell wall mutant of Saccharomyces cerevisiae and
the wild type," J Biochem (Tokyo) 98: 1301-1307. 1985.
Sietsma J.
H., et al., Journal of General Microbiology; 125:209-212. 1981.
Sietsma J.
H., et al., Journal of General Microbiology; 114:99-108. 1979.
Sima P., Vetvicka
V.; "Evolution of Immune Reactions," Critical Reviews in Immunology,
13: 83-114; 1993.
Sima P., Vetvicka
V.; "Evolution of Immune Reactions," CRC Press; 1990.
Smedsrod B,
Seljelid R, "Fate of intravenously injected aminated beta (1----3)
polyglucose derivatized with 125I-tyraminyl cellobiose," Immunophar
21(3): 149-158. May 1991. *
Song and Diluzio
N.R., Lysosomes in Biology and Pathology, Dingle et. al., eds.
North Holland Press Amsterdam; 6: 533-547. 1979.
Spiros J.;
Method for immune system activation by administration of a beta
(1-3) glucan which is produced by Saccharomyces cerevisiae strain
R4; U.S. Patent 5504079; 1996.
Spiros J.;
Use of neutral soluble glucan preparations to stimulate platelet
production; U.S. Patent 5488040; 1996.
Spiros J.,
Rha C., Sinskey AJ; "Glucan compositions and process for preparation
thereof," U.S. Patent 4810646; Issued Mar 7, 1989.
Stashenko,
et al., "Reduction of Infection-Stimulated Periapical Bone
Resorption by the Biological Response Modifier PGG Glucan",
J. Dent. Res.; 74(1): 323-330; 1995. * Dept of Cytokine Biology,
Forsyth Dental Ctr, Boston, MA. Quote: "PGG glucan-treated
animals had significantly less infection-stimulated periapical
bone resorption than control animals..."
Stashenko,
et al., "Inhibition of Periapical Bone Resorption by a
Biological Response Modifier", J. Dent. Res.; Res.73, No. 146.
1994.
Steadman R.,
Petersen M.M., et al; "Differential augmentation by recombinant
human tumor necrosis factor-alpha of neutrophil responses to particulate
zymosan and glucan," J. Immunol 144: 2712-2718. 1990. *
Stewart, et
al., "Preliminary Observations on the Effect of Glucan in Combination
with Radiation and Chemotherapy in Four Murine Tumors",
Cancer Treat. Prep.; 62: 1867-72. 1978.
Suga, et al.,
"Antitumor Activity of Lentinan in Murine Syngeneic and Autochthonons
Hosts and its Suppressive Effect on 3-Methylcholanthrene-induced
Carcinogenesis". Cancer Res.; 44: 5132-5137. 1984.
Surarit R.,
Gopal P.K., Shephard M.G.; "Evidence for a glycosidic linkage
between chitin and glucan in the cell wall of Candida albicans,"
J. Gen Microbiol 134: 1723-1730. 1988.
Suzuki T.,
Ohno N., Adachi Y., Yadomae T., "Serum components induce beta-D-glucan-inhibitable
uptake of zymosan particles by murine peritoneal macrophages,"
Biol Pharm Bull: 16: 223-227. 1993. *
Suzuki T.,
Ohno N., et al, "Activation of the complement system by (1--3)-beta-D-glucans
having different degrees of branching and different ultrastructures,"
J. Pharmacobiodyn 15: 277-285. 1992. *
Suzuki, Iwao,
Tanaka, Hideki, Konoshita, Akira, Oikawa, Shozo, Osawa, Masumi
and Yadomae. "Effects of Orally Administered beta-Glucan on Macrophage
Function in Mice". Toshiro, Journal of Immunopharmac; vol.
12, No. 6, pp. 675-684. 1990.
Sveinbjornsson
B, Seljelid R, "Aminated beta-1, 3-D-polyglucose activates salmon
pronephros macrophages in vitro," Vet Immunol Immunopathos
41(1-2): 113-123. May 1994.
Szabo T.,
Kadish J.L., Czop J.K.; "Biochemical properties of the ligand-binding
20-kDa of the beta-glucan receptors on the human mononuclear phagocytes,"
J. Biol Chem 270: 2145-2151. 1995. *
-
T - Back to Top
Tanaka S.,
Aketagawa J., et al, "Inhibition of high molecular weight (1-->3)-beta-D-glucan-dependent
activation of a limulus coagulation factor G by laminaran oligosaccharides
and curdlan degradation products," Carbohydr Res 244: 115-127;
1993. *
Tanaka, Immunopharmac.
and Immunotoxi.; 14:403-420. 1992. Tapper H., Sundler R.; "Glucan
receptor and zymosan-induced lysosomal enzyme secretion in macrophages,"
Biochem J. 306: 829-835. 1995. *
Thomsen, "Mouse
alpha-amylase synthesized by Saccharomyces cerevisiae is released
into the culture medium," Carlsberg Res. Comm., 48:545-555.
1983.
Thompson I.M.,
Spence C.R. Lamn DL., Diluzio N.R., "Immunochemotherapy of bladder
carcinoma with glucan and cyclophosphamide", Am. J. Med.
Sci. 294 (5): 294-300. 1987. *
Thornqvist
P.O., Hohansson M.W., Soderhall K.; "Opsonic activity of cell
adhesion proteins and beta-1-3-glucan binding proteins from two
crustaceans," Dev Comp Immunol 18: 3-12; 1994.
Thornton B.P.,
Vetvicka V., Pitman M., Goldman R.C., Ross G.D.; "Analysis of
the sugar specificity and molecular location of the beta-glucan-binding
lectin site of the complement receptor type 3 D11b/CD18)," J.
Immunol 156: 1235-1246. 1996.
Tikhomirov,
et al, "Endo-1, 4-beta-glucanases of the anaerobic bacterium Clostridium
thermocellum st. No. 3 with high heat stability," Chemical
Abstracts; 110:168879g.; 1989.
Todd, R.F.;
"The Continuing Saga of Complement Receptor Type 3 (CR3),"
J. Clin Invest.: Vol 98, 1-2. 1996. Div of Hematology/Oncology
Dept of Int. Med, U of Michigan Med Ctr.* Quote: (p2) "In certain
controlled clinical trials, the increased survival of patients
receiving these immunostimulatoryBeta-glucans has been reported."
Toews, et
al., J. Immuno.; 124:445-455. 1980.
Tomos et al.,
"A protein-glucan intermediate during paramylon synthesis"
Biochem. J.; 174:283-290. 1978.
Tong, D.W.,
Barnetson R.S.; B-1, 3-D-glucan gel in the treatment of solar
keratoses; Australasian J of Dermatology, 37: 137-138,
1996. * Dept of Dermat, Royal Prince Alfred Hosp, Camperdown,
Australia.
Truscheit
E., Bierling R., Schlumberger H., Oettgen H.; "Process for the
preparation of immunopotentiating agents from components of yeast
cell wall material; " U.S. Patent 4138479; Issued Feb 6, 1979.
*
Tsujinaka
T., Yokota M.K.; Modification of septic processes by B-glucan
administration. Eur Surg Res; 22:540-546, 1990. *
Tzianabos
AO, Cisneros RL; "Prophylaxis with the immunomodulator PGG glucan
enhances antibiotic efficacy in rats infected with antibiotic-resistant
bacteria, "Ann NY Acad Sci 797: 285-287; Oct 1996. * Quote:
"Results of these studies demonstrated that prophylaxis with
PGG glucan in combination with antibiotics provided enhanced protection
against lethal challenge with Escherichia coli or Staphylococcus
aureus as compared with the use of antibiotics alone."
-
U - Back to Top
Uchida, A.;
"Method for treatment of chronic fatigue syndrome, "U.S.
Patent 5424300 (A method for the treatment of chronic fatigue
syndrome, comprising administering a polysaccharide which further
contains a beta (1-3) glucan-1, 3/1, 6-glucoside bond). Issued
June 13, 1995.
-
V - Back to Top
Van Der Vaart
J.M., et al, and "The retention mechanism of cell wall proteins
in Saccharomyces cerevisiae Wall-bound Cwp2p is beta-1, 6-glucosylated,"
Biochim Biophys Acta, 1291(3): 206-214. Dept Molecular Cell
Biol, Utrecht U., The Netherlands. Dec 1996.
Van Der Vaart
J.M., et al, "The beta-1,6-glucan containing side-chain of cell
wall proteins of Saccharomyces cerevisiae is bound to the glucan
core of the GPI moiety," FEMS Microbiol Lett 145: 401-407.
1996.
Vargas-Albores
F., Jimenez-Vega, Soderhall K.; "A plasma protein isolated from
brown shrimp (Penaeus californiensis) which enhances the activation
of prophenoloxidase system by beta-1, 3-glucan," Dev Comp Immunol
20: 299-306. 1996.
Vetvicka V.,
Thornton B.P., Ross G.D.; "Soluble Beta-glucan Polysaccharide
Binding to the Lectin Site of Neutrophil or Natural Killer Cell
Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State
of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized
Target Cells," Journal Clin Invest 98: 50-61. 1996. Div of
Experimental Immuno and Immunopath, Dept Path, U of Louisville,
KY. * Quote: "This investigation showed that soluble CR3-specific
polysaccharides such as beta-glucan induced a primed state of
CR3 that could trigger killing of iC3b-target cells that were
otherwise resistant to cytotoxicity."
-
W - Back to Top
Wang, W.,
Duen-Horng W., et al; "Polysaccharide-Induced protection of Tilapia,
Tilapia aureus P., against Bacterial Infections in vivo,"
Dept of Veterinary Medicine.
Wessels J.G.;
"A beta 1,6-glucan glucanohydrolase involved in hydrolysis of
cell-wall glucan in Schizophyllum commune," Biochem Biophys
Acta 178: 191-193. 1969.
Williams D.L.
,Mueller A., Mueller P., Swails W., et al., "Randomized phase
I/II trial of a macrophage-specific immunomodulator (PGG-glucan)
in high-risk surgical patients". Ann. Surg.; 220(5):
601-609. 1994.
Williams D.L.,
et al, "A Sequential Multi-Assay Protocol for the Preclinical
Assessment of Natural Product Complex Carbohydrate Immunomodulators,"
Develop. Biol. Standard.; 77:129-136. 1992.
Williams D.L.,
et al,"Development of a Water-Soluble, Sulfated (1.fwdarw.3)-beta-D-Glucan
Biological Response Modifier Derived from Saccharomyces cerevisiae,"
Carbohydrate Research. 247-257. 1992.
Williams D.L.,
et al, Development, Physicochemical Characterization and Preclinical
Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived
from Saccharomyces cerevisiae," Immunopharmacology; 22:139-156.
1991.
Williams D.L.,
Mcnamee R.B., Jones E.L., et al., "A method for the solubilization
of a (1-2)-B-D-glucan isolated from Saccharomyces cerevisiae."
Carbohydr Res.; 219: 203-213. 1991.
Williams D.L.,
Browder I. and Diluzio N.R., "Soluble phosphorylated glucan: methods
and compositions for wound healing," U.S. Patent 4975421, Issued
Dec 4, 1990. Quote: "The soluble phosphorylated glucans
are useful for promoting the wound healing process. The soluble
phosphorylated glucans are also useful for prophylactic and therapeutic
applications against neoplastic, bacteria, viral, fungal and parasitic
diseases."
Williams D.L.,
Browder I. and Diluzio N.R., "Methods and compositions for prophylactic
and therapeutic treatment of infections," U.S. Patent 4900722,
Issued Feb 13, 1990. Quote: "The soluble phosphorylated
glucans are also useful for stimulating macrophage cells, either
in vivo or in vitro, to produce a cytotoxic/cyctostatic factor
effective against cancer cells."
Williams D.L.,
Sherwood E.R., Browder I.W., McNamee R.B., Jones E.L., Di Luzio
N.R.; Pre-clinical Safety Evaluation of Soluble Glucan.
International Journal Immunopharmac. 1988; 10: 405-411. 1988.
Williams D.L.,
et al; "Pre-clinical Safety Evaluation of Soluble Glucan",
Int. J. Immunophamac. Vol. 10, No. 4: 405-414. 1988. * Dept of
Phys, Tulane U Sch of Med, New Orleans, LA. *Quote: "Soluble
glucan, a beta-1, 3-linked glucopyranose biological response modifier,
is effective in the therapy of experimental neoplasia, infectious
diseases and immune suppression."
Williams D.L.,
et al; "Therapeutic efficacy of glucan in a murine model of hepatic
metastatic disease," Hepatology 5(2): 198-206. Mar 1985.
*Quote: "...coincubation of particulate glucan with diverse
populations of normal or tumor cells in vitro indicated that glucan
exerted a direct cytostatic effect on sarcoma and melanoma cells
and, in contrast, had a proliferative effect on normal spleen
and bone marrow cells."
Williams D.,
Browder IW and Diluzio N.R, "Immunotherapeutic modification of
Escherichia coli-induced experimental peritonitis and bacteremia
by glucan," Surgery 93(3): 448-454. Mar 1983. * Quote:
"These data denote that the intraperitoneal administration
of glucan significantly modifies the course of E. coli-induced
peritonitis and bacteremia due, in part, to glucan-induced enhancement
of macrophage function."
Williams D.L.
and Diluzio N.R.; "Modification of Experimental Viral Hepatitis
by Glucan Induced Macrophage Activation". In the Reticuloendothelial
System and Pathogenesis of Liver Disease, Liehr and Grun, eds.
Elsevier/North Holland Biomedical Press; pp. 363-368. 1983.
Williams D.L.,
et al.; Curr. Chemother and Infectious Disease, Proc.; 11th
1CC and 19th 1ICAAC pp. 1724-1726. 1980.
Williams D.L.
and Diluzio N.R.; "Glucan-Induced Modification of murine Viral
Hepatitis". Science (1980), 208: 67-69. 1980. *Quote: "Thus
glucan is capable of increasing survival, inhibiting hepatic necrosis,
and maintaining an activated state of phagocytic activity in mice
challenged with [mouse hepatitis virus strain] MHV-A59."
Williams D.L.,
et al; "Protective Effect of Glucan in Experimentally Induced
Candidiasis". J. Reticuloendothel; Soc 23: 479-490. 1978.
Williams D.L,
Diluzio NR, "Glucan induced modification of experimental Staphylococcus
aureus infection in normal, leukemic and immunosuppressed
mice." Adv Exp Med Biol 121(A): 291-306. 1979*
Williams D.L,
Diluzio NR, , Reticuloendothelial System and Pathogenesis of Liver
Disease; Liehr and Grun. eds. Solubilization of a (1-3_-B-D-glucan
isolated from Saccharomyces cerevisiae. Carbohydr. Res. 219:
203-213. 1991.
Wolk, M. and
Danon, D.; "Promotion of Wound Healing by Yeast Glucan
Evaluated on Single Animals"; Medical Biology; 63:73-80. 1985.
*
Wooles and
Diluzio N.R.; Proc. Soc. Exper. Biol, Med.; 115:756-759. 1964.
Wooles and
Diluzio N.R.; "The Phagocytic and Proliferative Responses of the
Reticuloendothelial System Following Glucan Administration". J.
Reticuloendothelial..; Soc. 1: 169-169. 1964.
Wooles, et
al.; "Influence of Pre- and post-X-Irradiation Zymosan Administration
on reticuloendothelial Function," Rad. Res.; 16: 546-554. 1962.
-
X -
-
Y - Back to Top
Yanki, et
al., "Correlation between the Antitumor Activity of a Polysaccharide
Schizophyllan and its Triple-Helical Conformation in Dilute Aqueous
Solution". Biophys. Chem. (1983) 17: 337-342.
Yoxhida M,
et al, "Soluble (1-->3)-beta-D-glucan purified from Candida
albicans: biologic effects and distribution in blood and organs
of rabbits," J Lab Clin Med 128(1): 103-114. Jul 1996. *Dept
of Lab Med, U of Cal Sch of Med, San Francisco, CA.
Yoshida H.,
Ochiai M., Ashida M.; "Beta-1, 3-glucan receptor and peptidoglycan
receptor are present as separate entities within insect prophenoloxidase
activating system," Biochem Biophys Res Commun 141: 1177-1184.
1986.
Yoshizawa,
et al, "Effects of Natural Human Interleukin-6 on Thrombopoiesis
and Tumor Progression in Tumor-Bearing Mice", Cancer Letters;
vol. 79, pp. 83-89. 1994.
